The development of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has revolutionized obesity therapy management due to their ability to achieve marked weight reduction (more than 15% in means) and improve clinical outcomes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.